Vivos Therapeutics | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 6.783 M

Revenue: As of FY2025 Q3, the actual value is USD 6.783 M, beating the estimate of USD 4.712 M.

EPS: As of FY2025 Q3, the actual value is USD -0.49.

EBIT: As of FY2025 Q3, the actual value is USD -4.247 M.

Product Revenue: $2.2 million for the three months ended September 30, 2025, compared to $1.9 million for the same period in 2024. For the nine months ended September 30, 2025, product revenue was $5.9 million, compared to $5.6 million in 2024.
Service Revenue: $4.6 million for the three months ended September 30, 2025, compared to $1.9 million for the same period in 2024. For the nine months ended September 30, 2025, service revenue was $7.7 million, compared to $5.7 million in 2024.
Total Revenue: $6.8 million for the three months ended September 30, 2025, compared to $3.9 million for the same period in 2024. For the nine months ended September 30, 2025, total revenue was $13.6 million, compared to $11.3 million in 2024.

Cost of Sales: $2.8 million for the three months ended September 30, 2025, compared to $1.5 million for the same period in 2024. For the nine months ended September 30, 2025, cost of sales was $6.1 million, compared to $4.4 million in 2024.
Gross Profit: $3.9 million for the three months ended September 30, 2025, compared to $2.3 million for the same period in 2024. For the nine months ended September 30, 2025, gross profit was $7.6 million, compared to $6.9 million in 2024.
Gross Margin: 58% for the three months ended September 30, 2025, compared to 60% for the same period in 2024. For the nine months ended September 30, 2025, gross margin was 55%, compared to 61% in 2024.

General and Administrative Expenses: $7.9 million for the three months ended September 30, 2025, compared to $4.5 million for the same period in 2024. For the nine months ended September 30, 2025, general and administrative expenses were $19.2 million, compared to $13.5 million in 2024.
Sales and Marketing Expenses: $0.4 million for the three months ended September 30, 2025, compared to $0.3 million for the same period in 2024. For the nine months ended September 30, 2025, sales and marketing expenses were $1.0 million, compared to $1.3 million in 2024.
Depreciation and Amortization: $0.4 million for the three months ended September 30, 2025, compared to $0.1 million for the same period in 2024. For the nine months ended September 30, 2025, depreciation and amortization were $0.9 million, compared to $0.4 million in 2024.

Operating Loss: $4.7 million for the three months ended September 30, 2025, compared to $2.6 million for the same period in 2024. For the nine months ended September 30, 2025, operating loss was $13.5 million, compared to $8.4 million in 2024.

Other Expense: $0.7 million for the three months ended September 30, 2025, compared to $0.02 million for the same period in 2024. For the nine months ended September 30, 2025, other expense was $0.9 million, compared to $0.04 million in 2024.
Other Income: $0.01 million for the three months ended September 30, 2025, compared to $0.05 million for the same period in 2024. For the nine months ended September 30, 2025, other income was $0.09 million, compared to $0.1 million in 2024.

Net Loss: $5.4 million for the three months ended September 30, 2025, compared to $2.6 million for the same period in 2024. For the nine months ended September 30, 2025, net loss was $14.3 million, compared to $8.3 million in 2024.

Net Cash Used in Operating Activities: $11.5 million for the nine months ended September 30, 2025, compared to $9.8 million for the same period in 2024.
Net Cash Used in Investing Activities: $5.9 million for the nine months ended September 30, 2025, compared to $0.4 million for the same period in 2024.
Net Cash Provided by Financing Activities: $14.2 million for the nine months ended September 30, 2025, compared to $14.8 million for the same period in 2024.

Integration of SCN: The company is focused on integrating SCN into its operations, with the goal of increasing diagnostic sleep testing revenue and related Vivos treatment center revenue. The company plans to deploy additional Sleep Optimization (SO) teams to meet patient demand and optimize operations.
Expansion Plans: The company is exploring additional acquisitions of, or collaborations with, medical sleep and similar healthcare practices to expand its business model and grow revenues.

Revised Management Model: The company is developing a revised strategic alliance or management model for sleep centers or medical practices that are not interested in being purchased but are interested in offering Vivos treatments. This model involves creating a new management services entity jointly owned by the sleep center owners and Vivos, with Vivos retaining a supermajority controlling interest.
Potential Provider Acquisition Pipeline: The company is in active discussions with potential acquisition targets and strategic sleep center affiliations. The pipeline of potential acquisition and management opportunities continues to expand, driven by word of mouth and minimal marketing efforts.

Revenue Growth and Positive Cash Flow: The company aims to achieve positive cash flow through the integration of SCN, additional acquisitions, and strategic alliances. The company is also focused on increasing revenue from its new sales, marketing, and distribution model.